Applied Therapeutics Competitors

Applied Therapeutics (NASDAQ:APLT) and Applied Molecular Transport (NASDAQ:AMTI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Institutional and Insider Ownership

54.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 52.0% of Applied Molecular Transport shares are held by institutional investors. 31.5% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Applied Therapeutics and Applied Molecular Transport's top-line revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of current ratings for Applied Therapeutics and Applied Molecular Transport, as reported by MarketBeat.

Applied Therapeutics currently has a consensus target price of $56.00, indicating a potential upside of ∞. Applied Molecular Transport has a consensus target price of $68.75, indicating a potential upside of 40.51%. Given Applied Therapeutics' higher probable upside, equities research analysts clearly believe Applied Therapeutics is more favorable than Applied Molecular Transport.

Profitability

This table compares Applied Therapeutics and Applied Molecular Transport's net margins, return on equity and return on assets.

Applied Therapeutics (NASDAQ:APLT) and Cytokinetics (NASDAQ:CYTK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Institutional and Insider Ownership

54.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 97.1% of Cytokinetics shares are held by institutional investors. 31.5% of Applied Therapeutics shares are held by insiders. Comparatively, 6.4% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Applied Therapeutics and Cytokinetics' top-line revenue, earnings per share and valuation.

Applied Therapeutics has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Applied Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Applied Therapeutics and Cytokinetics, as reported by MarketBeat.

Applied Therapeutics currently has a consensus target price of $56.00, indicating a potential upside of ∞. Cytokinetics has a consensus target price of $33.6364, indicating a potential upside of 39.22%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Applied Therapeutics is more favorable than Cytokinetics.

Profitability

This table compares Applied Therapeutics and Cytokinetics' net margins, return on equity and return on assets.

Summary

Applied Therapeutics beats Cytokinetics on 7 of the 13 factors compared between the two stocks.

Applied Therapeutics (NASDAQ:APLT) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Institutional and Insider Ownership

54.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 75.1% of FibroGen shares are held by institutional investors. 31.5% of Applied Therapeutics shares are held by insiders. Comparatively, 3.4% of FibroGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Applied Therapeutics and FibroGen's top-line revenue, earnings per share and valuation.

Applied Therapeutics has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Applied Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Applied Therapeutics and FibroGen, as reported by MarketBeat.

Applied Therapeutics currently has a consensus target price of $56.00, indicating a potential upside of ∞. FibroGen has a consensus target price of $45.8333, indicating a potential upside of 146.81%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Applied Therapeutics is more favorable than FibroGen.

Profitability

This table compares Applied Therapeutics and FibroGen's net margins, return on equity and return on assets.

Summary

Applied Therapeutics beats FibroGen on 7 of the 13 factors compared between the two stocks.

Applied Therapeutics (NASDAQ:APLT) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Institutional and Insider Ownership

54.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 26.7% of Cassava Sciences shares are held by institutional investors. 31.5% of Applied Therapeutics shares are held by insiders. Comparatively, 13.7% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Applied Therapeutics and Cassava Sciences' top-line revenue, earnings per share and valuation.

Cassava Sciences is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Applied Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Applied Therapeutics and Cassava Sciences, as reported by MarketBeat.

Applied Therapeutics currently has a consensus target price of $56.00, indicating a potential upside of ∞. Cassava Sciences has a consensus target price of $35.3333, indicating a potential downside of 15.00%. Given Applied Therapeutics' higher probable upside, equities research analysts clearly believe Applied Therapeutics is more favorable than Cassava Sciences.

Profitability

This table compares Applied Therapeutics and Cassava Sciences' net margins, return on equity and return on assets.

Summary

Cassava Sciences beats Applied Therapeutics on 5 of the 9 factors compared between the two stocks.

Applied Therapeutics (NASDAQ:APLT) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Institutional and Insider Ownership

54.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 40.9% of ADC Therapeutics shares are held by institutional investors. 31.5% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Applied Therapeutics and ADC Therapeutics, as reported by MarketBeat.

Applied Therapeutics currently has a consensus target price of $56.00, indicating a potential upside of ∞. ADC Therapeutics has a consensus target price of $47.50, indicating a potential upside of 98.00%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Applied Therapeutics is more favorable than ADC Therapeutics.

Profitability

This table compares Applied Therapeutics and ADC Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Applied Therapeutics and ADC Therapeutics' top-line revenue, earnings per share and valuation.

Applied Therapeutics has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Applied Therapeutics beats ADC Therapeutics on 6 of the 10 factors compared between the two stocks.

Myovant Sciences (NYSE:MYOV) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Institutional and Insider Ownership

33.8% of Myovant Sciences shares are held by institutional investors. Comparatively, 54.3% of Applied Therapeutics shares are held by institutional investors. 3.9% of Myovant Sciences shares are held by company insiders. Comparatively, 31.5% of Applied Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Myovant Sciences and Applied Therapeutics, as provided by MarketBeat.com.

Myovant Sciences currently has a consensus price target of $31.1667, indicating a potential upside of 71.72%. Applied Therapeutics has a consensus price target of $56.00, indicating a potential upside of ∞. Given Applied Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Applied Therapeutics is more favorable than Myovant Sciences.

Profitability

This table compares Myovant Sciences and Applied Therapeutics' net margins, return on equity and return on assets.

Volatility & Risk

Myovant Sciences has a beta of 2.99, indicating that its share price is 199% more volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500.

Earnings & Valuation

This table compares Myovant Sciences and Applied Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Myovant Sciences is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Applied Therapeutics beats Myovant Sciences on 8 of the 11 factors compared between the two stocks.